Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Juno Therapeutics

Status: Terminated

Conditions: Multiple Myeloma; Follicular Lymphoma; Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma

Treatments: Genetic: JCARH125; Genetic: JCAR017

Study type: Observational

Funder types: Industry

Identifiers

NCT03436771

LTFU001

Details and patient eligibility

About

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

Enrollment: 4 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have received at least one dose of a Juno CAR T-cell product (listed above) in a Juno-sponsored clinical trial
• Patients who have provided informed consent for the long-term follow-up study

Exclusion criteria

• None. All patients who have previously received treatment with a Juno CAR T-cell product are eligible for this long-term follow-up study.

Trial design

4 participants in 2 patient groups

JCAR017-treated

Description:

Patients who received previous treatment with JCAR017

Treatment:

Genetic: JCAR017

JCARH125-treated

Description:

Patients who received previous treatment with JCARH125

Treatment:

Genetic: JCARH125